Latest News and Press Releases

The applications for novel psychedelic-based combinations, developed with SciSparc, are based on monotherapy and novel combinations of SciSparc's Cannamide™ and classical psychedelics Tel Aviv,...

Dr. Adi Zuloff-Shani PhD., Clearmind’s chief executive officer will discuss its Nasdaq IPO with David Huberman, Capital Markets Shareholder at Greenberg Traurig law firm Tel Aviv, Israel /...

The conference will stream live on Tuesday, February 28, at 8:30 AM EST Tel Aviv, Israel / Vancouver, Canada, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:...

Tel Aviv, Israel / Vancouver, Canada, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the Company"), a biotech company focused on...

Isranalytica 2023, the Annual meeting of the Israel Analytical Chemical Society, provided Clearmind with the opportunity to garner visibility for its drug candidate MEAI from attendees at one of the...

The two drug-discovery projects for novel, next generation, innovative, patentable psychedelic compounds, are expected to expand Clearmind’s IP portfolio Tel Aviv, Israel / Vancouver, Canada, Jan. ...

The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of substance addiction without interrupting the natural reward...

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on...

In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv, Israel /...

Tel Aviv, Israel / Vancouver, Canada, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery...